FPAS
MYGN icon

Focus Partners Advisor Solutions’s Myriad Genetics MYGN Stock Holding History

Focus Partners Advisor Solutions’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,854
Closed -$72.9K – 1321
2025
Q4 		$72.9K Buy
11,854
+1,031
+10% +$7.48K ﹤0.01% 1062
2025
Q3 		$73.3K Buy
+10,823
New +$64.3K ﹤0.01% 1106

Other funds holding MYGN

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Focus Partners Advisor Solutions's MYGN Position: Q1 2026 in Review

Focus Partners Advisor Solutions sold out of Myriad Genetics (MYGN) in Q1 2026, closing a stake of 11,854 shares — an estimated $72.9K sold.

Focus Partners Advisor Solutions first reported a position in MYGN in Q3 2025 and held it in 2 quarters. The position peaked at $73.3K in Q3 2025. 203 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • Focus Partners Advisor Solutions reported no remaining Myriad Genetics position as of Q1 2026 after selling out during the quarter.
  • Focus Partners Advisor Solutions sold 11,854 Myriad Genetics shares in Q1 2026, an estimated $72.9K.
  • Focus Partners Advisor Solutions first reported a position in Myriad Genetics in Q3 2025 and held it in 2 quarters.
  • Focus Partners Advisor Solutions's Myriad Genetics position peaked at $73.3K in Q3 2025.
  • 203 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Focus Partners Advisor Solutions's 13F filing for Q1 2026, filed 13 May 2026.